financetom
Business
financetom
/
Business
/
Update: Dillard's Shares Rise After Fiscal Q3 Earnings, Revenue Beat Estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Dillard's Shares Rise After Fiscal Q3 Earnings, Revenue Beat Estimates
Nov 13, 2025 9:49 AM

12:37 PM EST, 11/13/2025 (MT Newswires) -- (Updates stock movement in the first paragraph.)

Dillard's (DDS) shares jumped 22% in recent Thursday trading after the company posted fiscal Q3 results that beat analyst expectations.

Earnings in the 13 weeks ended Nov. 1 rose to $8.31 per diluted share from $7.73 a year earlier, the company said Thursday.

Three analysts polled by FactSet expected $6.26.

Net sales rose to $1.47 billion from $1.43 billion a year earlier.

Three analysts surveyed by FactSet expected $1.43 billion.

Price: 737.73, Change: +131.77, Percent Change: +21.75

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BTG Pactual's Andre Esteves expected to join Eneva's board
BTG Pactual's Andre Esteves expected to join Eneva's board
Mar 28, 2025
SAO PAULO, March 28 (Reuters) - The chairman of Brazil's investment bank BTG Pactual, billionaire Andre Esteves, is expected to join the board of power generator Eneva , according to a proposal released on Friday for Eneva's shareholders' meeting. Under the proposal, Eneva's board of directors, composed of seven members, would see two new members as two others exit. Rodrigo...
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Why Is Milestone Pharmaceuticals Stock Plunging Today?
Mar 28, 2025
Milestone Pharmaceuticals Inc. ( MIST ) announced on Friday that its New Drug Application for CARDAMYST (etripamil) nasal spray, aimed at treating acute episodes of paroxysmal supraventricular tachycardia, received a Complete Response Letter from the U.S. Food and Drug Administration (FDA). The company’s shares are trading lower following the news. While the FDA did not raise concerns about the clinical...
Liquidia Says FDA to Review New Drug Application for Yutrepia
Liquidia Says FDA to Review New Drug Application for Yutrepia
Mar 28, 2025
10:04 AM EDT, 03/28/2025 (MT Newswires) -- Liquidia ( LQDA ) said Friday the US Food and Drug Administration accepted its resubmitted new drug application for Yutrepia inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company said the FDA classified the resubmission as a complete, Class 1 response to an August 2024...
Knightscope Launches $1.7 Million Registered Direct Offering
Knightscope Launches $1.7 Million Registered Direct Offering
Mar 28, 2025
09:52 AM EDT, 03/28/2025 (MT Newswires) -- Knightscope ( KSCP ) said Friday it has launched a registered direct offering of 625,000 common shares at $2.75 apiece to raise about $1.7 million in gross proceeds. The offering will likely be completed around March 31, the company said. Knightscope ( KSCP ) also said it plans to allocate the net proceeds...
Copyright 2023-2026 - www.financetom.com All Rights Reserved